| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2567972 | Pulmonary Pharmacology & Therapeutics | 2006 | 10 Pages |
Abstract
In conclusion, the in vitro inhibitory and bactericidal activities exhibited by ulifloxacin and the favorable characteristics shown by its prodrug (prulifloxacin) in clinical trials, particularly indicate this drug for the treatment of lung and urinary infections.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Maria Gabriella Matera,